The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Fluvoxamine versus other anti-depressive agents for depression
Open accessAbstract
BACKGROUND: Fluvoxamine, one of the oldest selective serotonin reuptake inhibitors (SSRIs), is prescribed to patients with major depression in many countries. Several studies have previously reviewed the efficacy and tolerability of fluvoxamine for the treatment of major depression. However, these reviews are now outdated. OBJECTIVES: Our objective is to evaluate the effectiveness, tolerability and side effect profile of fluvoxamine for major depression in comparison with other anti-depressive agents, including tricyclics (TCAs), heterocyclics, other SSRIs, SNRIs, other newer agents and other conventional psychotropic drugs. SEARCH STRATEGY: We searched the Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register. Trial databases and ongoing trial registers in North America, Europe, Japan and Australia, were handsearched for randomised controlled trials. We checked reference lists of the articles included in the review, previous systematic reviews and major textbooks of affective disorder for published reports and citations of unpublished research. The date of last search was 31 August 2008. SELECTION CRITERIA: We included all randomised controlled trials, published in any language, that compared fluvoxamine with any other active antidepressants in the acute phase treatment of major depression. DATA COLLECTION AND ANALYSIS: Two independent review authors inspected citations and abstracts, obtained papers, extracted data and assessed the risk of bias of included studies. We analysed dichotomous data using odds ratios (ORs) and continuous data using the standardised mean difference (SMD). A random effects model was used to combine studies. MAIN RESULTS: A total of 54 randomised controlled trials (n = 5122) were included. No strong evidence was found to indicate that fluvoxamine was either superior or inferior to other antidepressants regarding response, remission and tolerability. However, differing side effect profiles were evident, especially with regard to gastrointestinal side effects of fluvoxamine when compared to other antidepressants. For example, fluvoxamine was generally associated with a higher incidence of vomiting/nausea (versus imipramine, OR 2.23, CI 1.59 to 3.14; versus clomipramine, OR 2.13, CI 1.06 to 4.27; versus amitriptyline, OR 2.86, CI 1.31 to 2.63). AUTHORS' CONCLUSIONS: We found no strong evidence that fluvoxamine was either superior or inferior to any other antidepressants in terms of efficacy and tolerability in the acute phase treatment of depression. However, differing side effect profiles were evident. Based on these findings, we conclude that clinicians should focus on practical or clinically relevant considerations, including these differences in side effect profiles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2005) · CHANCE · doi:10.1080/09332480.2005.10722754 · Cited by 4,702
The Whoqol Group (1998) · Social Science & Medicine · doi:10.1016/s0277-9536(98)00009-4 · Cited by 3,802
Improving the Quality of Reporting of Randomized Controlled Trials: The CONSORT Statement
Begg, C. (1996) · JAMA · doi:10.1001/jama.1996.03540080059030 · Cited by 3,127
Meta-analyses involving cross-over trials: methodological issues
Elbourne, D. R., Altman, D. G., Higgins, J. P., Curtin, F., Worthington, H. V., & Vail, A. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.140 · Cited by 2,305
Publication and related bias in meta-analysis
Sterne, J. A. C., Gavaghan, D., & Egger, M. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00242-0 · Cited by 2,282
Pharmaceutical industry sponsorship and research outcome and quality: systematic review
Lexchin, J., Bero, L. A., Djulbegovic, B., & Clark, O. (2003) · BMJ · doi:10.1136/bmj.326.7400.1167 · Cited by 2,147
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Self-citationImputing missing standard deviations in meta-analyses can provide accurate results
Furukawa, T. A., Barbui, C., Cipriani, A., Brambilla, P., & Watanabe, N. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.06.006 · Cited by 1,568
Self-citationThe Economic Burden of Depression in the United States: How Did It Change Between 1990 and 2000?
Greenberg, P. E., Kessler, R. C., Birnbaum, H. G., Leong, S. A., Lowe, S. W., Berglund, P. A., & Corey-Lisle, P. K. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1211 · Cited by 1,280
Statistics Notes: Detecting skewness from summary information: Table 1
Altman, D. G., & Bland, J. M. (1996) · BMJ · doi:10.1136/bmj.313.7066.1200 · Cited by 1,278
Network meta‐analysis for indirect treatment comparisons
Lumley, T. (2002) · Statistics in Medicine · doi:10.1002/sim.1201 · Cited by 1,206
Evaluation of networks of randomized trials
Salanti, G., Higgins, J. P., Ades, A., & Ioannidis, J. P. (2008) · Statistical Methods in Medical Research · doi:10.1177/0962280207080643 · Cited by 1,078
A consumer's guide to subgroup analyses
Oxman, A. D., & Guyatt, G. H. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-1-78 · Cited by 914
Als-Nielsen, B., Chen, W., Gluud, C., & Kjaergard, L. L. (2003) · JAMA · doi:10.1001/jama.290.7.921 · Cited by 746
Montejo-gonzàlez, A. L., Llorca, G., Izquierdo, J. A., Ledesma, A., Bousono, M., Calcedo, A., Carrasco, J. L., Ciudad, J., Daniel, E., De LA Gandara, J., et al. (1997) · Journal of Sex & Marital Therapy · doi:10.1080/00926239708403923 · Cited by 505
Taylor, M. J., Freemantle, N., Geddes, J. R., & Bhagwagar, Z. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.11.1217 · Cited by 406
Imputing response rates from means and standard deviations in meta-analyses
Furukawa, T. A., Cipriani, A., Barbui, C., Brambilla, P., & Watanabe, N. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200501000-00010 · Cited by 337
Self-citationPerlis, R. H., Perlis, C. S., Wu, Y., Hwang, C., Joseph, M., & Nierenberg, A. A. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.10.1957 · Cited by 318
Furukawa, T. A., Guyatt, G. H., & Griffith, L. E. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.72 · Cited by 318
Self-citationMüller, M. (2003) · Journal of Affective Disorders · doi:10.1016/s0165-0327(02)00120-9 · Cited by 282
Bollini, P., Pampaliona, S., Tibaldi, G., Kupelnick, B., & Munizza, C. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.174.4.297 · Cited by 274
Escitalopram versus other antidepressive agents for depression
Cipriani, A., Santilli, C., Furukawa, T. A., Signoretti, A., Nakagawa, A., McGuire, H., Churchill, R., & Barbui, C. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006532.pub2 · Cited by 190
Self-citationThe economic burden of depression in the US: societal and patient perspectives
Greenberg, P. E., & Birnbaum, H. G. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.3.369 · Cited by 166
Changes in daily life experience associated with clinical improvement in depression
Barge-Schaapveld, D. (1995) · Journal of Affective Disorders · doi:10.1016/0165-0327(95)00012-c · Cited by 84
24-Hour motor activity after treatment with imipramine or fluvoxamine in major depressive disorder
Volkers, A. (2002) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(02)00019-6 · Cited by 56
Kasper, S., Möller, H. J., Montgomery, S. A., & Zondag, E. (1995) · International Clinical Psychopharmacology · doi:10.1097/00004850-199501004-00001 · Cited by 37
Research works printed but not linked: 217
- Amore, 1989, Double-blind comparison of fluvoxamine and imipramine in depressed patients, Current Therapeutic Research, Clinical & Experimental, 46, 815
- Ansseau, 1991, Interest of a loading dose of milnacipran in endogenous depressive inpatients. Comparison with the standard regimen and with fluvoxamine, European Neuropsychopharmacology, 1, 113, 10.1016/0924-977X(91)90712-4 · DOI
- Ansseau, 1991, Interest of a loading dose of milnacipran in endogenous depressive inpatients. Comparison with the standard regimen and with fluvoxamine, European Neuropsychopharmacology, 1, 113, 10.1016/0924-977X(91)90712-4 · DOI
- Ansseau, 1993, A double-blind comparison of paroxetine and fluvoxamine in major depression, European Neuropsychopharmacology, 3, 323, 10.1016/0924-977X(93)90099-8 · DOI
- Ansseau, 1994, Controlled comparison of paroxetine and fluvoxamine in major depression, Human Psychopharmacology, 9, 329, 10.1002/hup.470090502 · DOI
- Asakura, 2005, A randomized, double-blind study of fluvoxamine maleate in patients with depression or depressive state: A comparison in anticholinergic effects and cardiovascular adverse reactions between fluvoxamine maleate and imipramine hydrochloride, Japanese Pharmacology and Therapeutics, 33, 773
- Barrelet, 1991, Multicenter study comparing efficacy and tolerance of moclobemide and fluvoxamine in hospitalized and ambulatory patients with severe depressive episodes, Schweizerische Rundschau fur Medizin Praxis, 80, 524
- Bocksberger, 1993, Comparison of the efficacy of moclobemide and fluvoxamine in elderly patients with a severe depressive episode, European Psychiatry: the Journal of the Association of European Psychiatrists, 8, 319, 10.1017/S0924933800000705 · DOI
- Bocksberger, 1992, Comparison of the efficacy and tolerability of moclobemide and fluvoxamine in elderly patients, Clinical Neuropharmacology, 15(1 Pt B), 146, 10.1097/00002826-199202001-00282 · doi:10.1097/00002826-199202001-00282
- Bougerol, 1992, Efficacy and tolerability of moclobemide compared with fluvoxamine in depressive disorder (DSM III) A French/Swiss double-blind trial, Psychopharmacology, 106[Suppl], S102, 10.1007/BF02246249 · DOI
- Bramanti, 1988, An Italian multicenter experience with fluvoxamine, a new antidepressant drug, versus imipramine, Current Therapeutic Research, Clinical & Experimental., 43, 718
- Brown, 1986, Pituitary-adrenocortical hyperfunction and intolerance to fluvoxamine, a selective serotonin uptake inhibitor, American Journal of Psychiatry, 143, 88, 10.1176/ajp.143.1.88 · doi:10.1176/ajp.143.1.88
- Brunner, 1994, A randomised, parallel group comparison of fluvoxamine and amineptine in patients with marked depression, British Journal of Clinical Research, 5, 101
- Amin, 1984, Fluvoxamine:antidepressant effects confirmed in a placebo-controlled international study, Clinical Neuropharmacology, 7[Suppl 1], 580
- Cassano, 1986, Use of a standardized documentation system (BLIPS/BDP) in the conduct of a multicenter international trial comparing fluvoxamine, imipramine, and placebo, Psychopharmacology Bulletin, 22, 52
- Conti, 1989, Clinical predictors of response to fluvoxamine, imipramine, and placebo, New Trends in Experimental and Clinical Psychiatry, 5, 221
- Conti, 1987, Therapeutic response in subtypes of major depression, New Trends in Experimental and Clinical Psychiatry, 3, 101
- Dominguez, 1985, A double-blind placebo-controlled study of fluvoxamine and imipramine in depression, Journal of Clinical Psychiatry, 46, 84
- Lapierre, 1987, Treatment of major affective disorder with fluvoxamine, Journal of Clinical Psychiatry, 48, 65
- Norton, 1984, A double-blind comparison of fluvoxamine, imipramine and placebo in depressed patients, Journal of Affective Disorders, 7, 297, 10.1016/0165-0327(84)90051-X · DOI
- Ottevanger, 1991, The efficacy of fluvoxamine in patients with severe depression, British Journal of Clinical Research, 2, 125
- Ottevanger, 1994, The efficacy of fluvoxamine in patients with severe depression, Progress in Neuro-Psychopharmacology & Biological Psychiatry, 18, 731, 10.1016/0278-5846(94)90080-9 · DOI
- Ottevanger, 1991, The efficacy of fluvoxamine in patients with severe depression, Psychologie Medicale, 23, 1639
- Wagner, 1986, Influence of concomitant psychotropic medication on the efficacy and tolerance of fluvoxamine, Advances in Pharmacotherapy, 2, 34
- Wakelin, 1986, Fluvoxamine in the treatment of the older depressed patient; double-blind, placebo-controlled data, International Clinical Psychopharmacology, 1, 221, 10.1097/00004850-198607000-00005 · DOI
- Claghorn, 1996, Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients, Journal of Clinical Psychopharmacology, 16, 113, 10.1097/00004714-199604000-00003 · DOI
- Clerc, 2001, Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: A comparison with fluvoxamine, International Clinical Psychopharmacology, 16, 145, 10.1097/00004850-200105000-00003 · DOI
- Coleman, 1982, Fluvoxamine maleate, a serotonergic antidepressant; A comparison with chlorimipramine, Progress in Neuro-Psychopharmacological & Biological Psychiatry, 6, 475, 10.1016/S0278-5846(82)80132-2 · DOI
- Dalery, 2003, Fluvoxamine versus fluoxetine in major depressive episode: A double-blind randomised comparison, Human Psychopharmacology, 18, 379, 10.1002/hup.490 · DOI
- Strik, 1998, Cardiac side-effects of two selective serotonin reuptake inhibitors in middle-aged and elderly depressed patients, International Clinical Psychopharmacology, 13, 263, 10.1097/00004850-199811000-00004 · doi:10.1097/00004850-199811000-00004
- Wilde, 1983, Clinical trials of fluvoxamine vs chlorimipramine with single and three times daily dosing, British Journal of Clinical Pharmacology, 15, 427S
- Dick, 1983, A double-blind comparative study of the clinical efficacy of fluvoxamine and chlorimipramine, British Journal of Clinical Pharmacology, 15, 419S
- Fabre, 1996, Fluvoxamine versus imipramine and placebo: A double-blind comparison in depressed patients, International Clinical Psychopharmacology, 11, 119
- Fabre, 1992, Fluvoxamine in the treatment of depression - A double-blind comparison with imipramine and placebo in outpatients with major depression, Clinical Neuropharmacology, 15, 416, 10.1097/00002826-199202001-00809 · doi:10.1097/00002826-199202001-00809
- Feighner, 1989, A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression, International Clinical Psychopharmacology, 4, 239, 10.1097/00004850-198907000-00006 · DOI
- Gonul, 1999, Selective serotonin reuptake inhibitors: discontinuation rates due to side effects, European Neuropsychopharmacology, 9(Suppl 5), 215, 10.1016/S0924-977X(99)80132-1 · doi:10.1016/s0924-977x(99)80132-1
- Guy, 1984, A double-blind clinical trial of fluvoxamine and imipramine in patients with primary depression, Psychopharmacology Bulletin, 20, 73
- Hackett D Salinas E Desmet A Efficacy and safety of venlafaxine vs. fluvoxamine in outpatients with major depression 11th European College of Neuropsychopharmacology Congress 1998 · DOI
- Hackett D Salinas E Desmet A Efficacy and safety of venlafaxine vs. fluvoxamine in outpatients with major depression 11th European College of Neuropsychopharmacology Congress 1998 · DOI
- Haffmans, 1996, Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study The lucifer group, International Clinical Psychopharmacology, 11, 157, 10.1097/00004850-199609000-00002 · DOI
- Timmerman L Haffmans PMJ Hoogduin CA Citalopram in major depression: a comparative study with Fluvoxamine, Preliminary results Past, Present and Future of Psychiatry (IX World Congress of Psychiatry - 9th 1993 Rio de Janiero, Brazil) River Edge, NJ World Scientific 1994 982 6 · doi:10.1142/9789814440912_0212
- Harris, 1991, Fluvoxamine versus amitriptyline in depressed hospital out-patients: a multicentre double-blind comparative trial, British Journal of Clinical Research, 2, 88
- Whitehead, 1992, Fluvoxamine in the treatment of depressive illness. A series of double-blind hospital based comparative studies carried out in the UK, British Journal of Clinical Practice, 46, 21
- Itil, 1983, A double-blind placebo-controlled study of fluvoxamine and imipramine in out-patients with primary depression, British Journal of Clinical Pharmacology, 15(Suppl 3), 433S
- Kasper, 1993, Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects, European Neuropsychopharmacology, 3, 13, 10.1016/0924-977X(93)90290-3 · DOI
- Kasper, 1991, Therapeutic sleep deprivation and antidepressant medication in patients with major depression, European Neuropsychopharmacology, 1, 107, 10.1016/0924-977X(91)90711-3 · DOI
- Kasper, 1992, Auditory evoked potentials and treatment with specific acting antidepressants, Clinical Neuropharmacology, 15, 152, 10.1097/00002826-199202001-00293 · doi:10.1097/00002826-199202001-00293
- Kasper, 1992, Plasma levels of fluvoxamine and maprotiline and clinical response in major depression, Pharmacopsychiatry, 25, 106
- Kasper, 1990, Response to total sleep deprivation before and during treatment with fluvoxamine or maprotiline in patients with major depression; results of a double-blind study, Pharmacopsychiatry, 23, 135, 10.1055/s-2007-1014496 · DOI
- Kasper, 1989, Stimulation with dl-fenfluramine and antidepressive medication in major depressed inpatients, Pharmacopsychiatry, 22, 201
- Kato, 2006, Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients, Neuropsychobiology, 53, 186, 10.1159/000094727 · DOI · Paper page
- Kato, 2005, Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism, International Clinical Psychopharmacology, 20, 151, 10.1097/00004850-200505000-00005 · DOI
- Kato, 2004, Clinical comparison of paroxetine and fluvoxamine considering of the serotonin transporter promoter polymorphism in patients with affective disorder, International Clinical Psychopharmacology, 19, 175, 10.1097/00004850-200405000-00012 · DOI
- Kavoussi, 1999, Prolactin response to d-fenfluramine in major depression before and after treatment with serotonin reuptake inhibitors, Biological Psychiatry, 45, 295, 10.1016/S0006-3223(98)00147-4 · doi:10.1016/s0006-3223(98)00147-4
- Kiev, 1997, A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients, Journal of Clinical Psychiatry, 58, 146, 10.4088/JCP.v58n0402 · DOI · Paper page
- Koetsier, 2002, CPT performance in major depressive disorder before and after treatment with imipramine or fluvoxamine, Journal of Psychiatric Research, 36, 391, 10.1016/S0022-3956(02)00026-2 · DOI
- Volkers, 2004, Effects of imipramine, fluvoxamine,and depressive mood on autonomic cardiac functioning in major depressive disorder, Pharmacopsychiatry, 37, 18, 10.1055/s-2004-815470 · DOI
- Kostiukova, 2003, Comparative efficacy and tolerance of fluvoxamine and amitriptyline in the treatment of moderate and severe depression in mental hospital, Zhurnal Nevrologii i Psikhiatrii Imeni SS Korsakova, 103, 24
- Brady, 1994, A comparison of the effects of imipramine and fluvoxamine on the thyroid axis, Biological Psychiatry, 36, 778, 10.1016/0006-3223(94)90092-2 · DOI
- Johnson, 1993, Effect of fluvoxamine, imipramine and placebo on catecholamine function in depressed outpatients, Journal of Psychiatric Research, 27, 161, 10.1016/0022-3956(93)90004-L · doi:10.1016/0022-3956(93)90004-l
- Laird, 1993, Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients, Journal of Clinical Psychiatry, 54, 224
- Lydiard, 1989, Fluvoxamine, imipramine, and placebo in the treatment of depressed outpatients: effects on depression, Psychopharmacology Bulletin, 25, 68
- March, 1990, A double-blind, placebo-controlled trial of fluvoxamine versus imipramine in outpatients with major depression, Journal of Clinical Psychiatry, 51, 200
- Mendonca Lima, 1997, Maprotiline versus fluvoxamine: comparison of their effects on the hypothalamo-hypophyseal-thyroid axis, Encephale, 23, 48
- Miller, 2001, Noradrenergic function and clinical outcome in antidepressant pharmacotherapy, Neuropsychopharmacology, 24, 617, 10.1016/S0893-133X(00)00232-3 · DOI
- Moon, 1991, The effects of psychomotor performance of fluvoxamine versus mianserin in depressed patients in general practice, British Journal of Clinical Practice, 45, 259
- Mullin, 1998, A double-blind comparison of fluvoxamine and dothiepin in the treatment of major affective disorder, British Journal of Clinical Practice, 42, 51
- Whitehead, 1992, Fluvoxamine in the treatment of depressive illness. A series of double-blind hospital based comparative studies carried out in the UK, British Journal of Clinical Practice, 46, 21
- Murasaki, 1998, Clinical evaluation of sme3110 (fluvoxamine maleate) in the treatment of depression and depressive state: a double-blind, comparative study with amitriptyline, Rinsyoiyaku (Journal of clinical therapeutics & medicine), 14, 951
- Kupfer, 1991, Fluvoxamine versus desipramine: Comparative polysomnographic effects, Biological Psychiatry, 29, 23, 10.1016/0006-3223(91)90208-4 · DOI · Paper page
- Nathan, 1990, The role of neuropharmacologic selectivity in antidepressant action: fluvoxamine versus desipramine, Journal of Clinical Psychiatry, 51, 367
- Nemeroff C Ninan P Ballenger J Feighner J Greist J Patterson W Comparison of the safety and tolerance of fluvoxamine and sertraline in depressed outpatients 8th ECNP (European College of Neuropsychopharmacology) Congress Venice, Italy 1995 · DOI
- Nemeroff, 1995, Double-blind multicenter comparison of fluvoxamine versus sertraline in the treatment of depressed outpatients, Depression, 3, 163, 10.1002/depr.3050030402 · DOI
- Otsubo, 2005, A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression, Pharmacopsychiatry, 38, 30, 10.1055/s-2005-837769 · doi:10.1055/s-2005-837769
- Ottevanger, 1995, Fluvoxamine and clomipramine in depressed hospitalised patients: results from a randomised, double-blind study, Encephale, 21, 317
- Perez, 1990, A double-blind, randomized comparison of fluvoxamine with mianserin in depressive illness, Current Medical Research and Opinion, 12, 234, 10.1185/03007999009111652 · DOI · Paper page
- Whitehead, 1992, Fluvoxamine in the treatment of depressive illness. A series of double-blind hospital based comparative studies carried out in the UK, British Journal of Clinical Practice, 46, 21
- Rahman, 1991, A double-blind, randomised comparison of fluvoxamine with dothiepin in the treatment of depression in elderly patients, British Journal of Clinical Practice, 45, 255
- Whitehead, 1992, Fluvoxamine in the treatment of depressive illness. A series of double-blind hospital based comparative studies carried out in the UK, British Journal of Clinical Practice, 46, 21
- Rapaport M Coccaro E Sheline Y Holland P Perse T Fabre L Bradford D Comparison of fluvoxamine and fluoxetine in major depression 8th ECNP (European College of Neuropsychopharmacology) Congress Venice, Italy 1995 · doi:10.1016/0924-977x(95)90453-k
- Rapaport, 1996, A comparison of fluvoxamine and fluoxetine in the treatment of major depression, Journal of Clinical Psychopharmacology, 16, 373, 10.1097/00004714-199610000-00005 · DOI
- Rechlin, 1994, The effect of amitriptyline, doxepin, fluvoxamine, and paroxetine treatment on heart rate variability, Journal of Clinical Psychopharmacology, 14, 392, 10.1097/00004714-199412000-00004 · DOI
- Remick, 1994, Comparison of fluvoxamine and amitriptyline in depressed outpatients, Current Therapeutic Research, Clinical and Experimental, 55, 243, 10.1016/S0011-393X(05)80168-7 · DOI
- Rossini, 2002, Sertraline versus fluvoxamine in the treatment of elderly patients with major depression: A double-blind, randomised trial, European Neuropsychopharmacology, 12, S251, 10.1016/S0924-977X(02)80321-2 · doi:10.1016/s0924-977x(02)80321-2
- Rossini, 2005, Sertraline versus fluvoxamine in the treatment of elderly patients with major depression: A double-blind, randomized trial, Journal of Clinical Psychopharmacology, 25, 471, 10.1097/01.jcp.0000177548.28961.e7 · DOI
- Rota, 2005, Neuroendocrine (HPA axis) and clinical correlates during fluvoxamine and amitriptyline treatment, Psychiatry Research, 133, 281, 10.1016/j.psychres.2003.12.030 · DOI
- Schoemaker, 2002, First, randomized, double-blind comparison of mirtazapine (15-45 mg) and fluvoxamine (50-150 mg) in the treatment of depression, International Journal of Neuropsychopharmacology, 5, 140
- Tourigny-Rivard M Nair N Vincent P Fluvoxamine versus desipramine in elderly patients with major depression: A double-blind comparison 9th ECNP (European College of Neuropsychopharmacology) Congress Amsterdam, Netherlands 1996 · doi:10.1016/0924-977x(96)83081-1
- Ueda, 2002, Plasma levels of catecholamine metabolites predict the response to sulpiride or fluvoxamine in major depression, Pharmacopsychiatry., 35, 175, 10.1055/s-2002-34116 · DOI
- Katz, 1993, Drug treatment of depression in the frail elderly, discussion of the NIH consensus development conference on the diagnosis and treatment of depression late-life, Psychopharmacology Bulletin, 29, 101
- Wagner, 1994, Fluvoxamine. A review of its safety profile in world-wide studies, International Clinical Psychopharmacology, 9, 222, 10.1097/00004850-199400940-00001 · DOI
- Zohar, 2003, Fluvoxamine as effective as clomipramine against symptoms of severe depression: results from a multicentre, double-blind study, Human Psychopharmacology, 18, 113, 10.1002/hup.442 · DOI
- Baicsher, 1991, Clinical use of fluvoxamine in selected outpatients with depression, anxiety, and eating disorders, Pakistan Journal of Clinical Psychiatry, 3, 143
- Bellini, 1992, A standardized treatment for delusional depression: Preliminary results, Clinical Neuropharmacology, 15(1 Pt B), 413, 10.1097/00002826-199202001-00802 · doi:10.1097/00002826-199202001-00802
- Blier, 1997, Selective activation of postsynaptic 5-HT(1A) receptors induces rapid antidepressant response, Neuropsychopharmacology, 16(5), 333, 10.1016/S0893-133X(96)00242-4 · DOI · Paper page
- Davis, 1991, Deuterium-labelled p-tyramine challenge test and phenolsulfotransferase activity in depressed patients- Failure to replicate decreased p-tyramine conjugation in depression, Progress in Neuro-psychopharmacology & Biological Psychiatry, 15, 241, 10.1016/0278-5846(91)90087-H · doi:10.1016/0278-5846(91)90087-h
- Jonghe, 1991, Randomized double-blind study of fluvoxamine and maprotiline in treatment of depression, Pharmacopsychiatry, 24, 21, 10.1055/s-2007-1014428 · DOI
- Kemp, 2002, Diagnosis at the first episode to differentiate antidepressant treatment responses in patients with mood and anxiety disorders, Psychopharmacology, 160, 67, 10.1007/s00213-001-0947-4 · DOI
- Wilde, 1982, Fluvoxamine and chlorimipramine in endogenous depression, Journal of Affective Disorders, 4, 249, 10.1016/0165-0327(82)90009-X · DOI
- Emrich, 1987, Serotonin reuptake inhibition vs norepinephrine reuptake inhibition: a double-blind differential-therapeutic study with fluvoxamine and oxaprotiline in endogenous and neurotic depressives, Pharmacopsychiatry, 20, 60, 10.1055/s-2007-1017076 · DOI
- Entsuah, 2002, A critical examination of the sensitivity of unidimensional subscales derived from the Hamilton Depression Rating Scale to antidepressant drug effects, Journal of Psychiatric Research, 36, 437, 10.1016/S0022-3956(02)00024-9 · DOI
- Franchini, 1997, Four-year follow-up study of sertraline and fluvoxamine in long-term treatment of unipolar subjects with high recurrence rate, Journal of Affective Disorders, 58, 233, 10.1016/S0165-0327(99)00113-5 · DOI
- Gasperini, 1992, Perspectives in clinical psychopharmacology of amitriptyline and fluvoxamine A double-blind study in depressed inpatients, Neuropsychobiology, 26, 186, 10.1159/000118918 · DOI
- Gonella, 1990, Fluvoxamine and imipramine in the treatment of depressive patients: a double-blind controlled study, Current Medical Research and Opinion, 12, 177, 10.1185/03007999009111499 · DOI
- Goto, 2006, Treatment of anxiety and depression-related vertigo and dizziness with SSRIs and SNRIs, Equilibrium Research, 65, 17, 10.3757/jser.65.17 · DOI
- Guelfi, 1983, A double-blind controlled clinical trial comparing fluvoxamine with imipramine, British Journal of Clinical Pharmacology, 15, 411
- Guelfi, 1987, Fluvoxamine and imipramine: results of a long-term controlled trial, International Clinical Psychopharmacology, 2, 103, 10.1097/00004850-198704000-00002 · DOI
- Harris, 1991, Maintenance antidepressants and weight gain: A comparison of fluvoxamine and amitriptyline, British Journal of Clinical Research, 2, 81
- Hewer, 1995, Cardiovascular effects of fluvoxamine and maprotiline in depressed patients, European Archives of Psychiatry and Clinical Neuroscience, 246, 1, 10.1007/BF02191808 · DOI
- Hewer, 1994, Effects of fluvoxamine and maprotiline on ECG parameters, Nervenheilkunde, 13, 375
- Hochberg, 1995, Electrocardiographic findings during extended clinical trials of fluvoxamine in depression: one year's experience, Pharmacopsychiatry, 28, 253, 10.1055/s-2007-979612 · DOI
- Khan, 1989, Onset of response in relation to outcome in depressed outpatients with placebo and imipramine, Journal of Affective Disorders, 17, 33, 10.1016/0165-0327(89)90021-9 · DOI
- Khan, 1991, Chronicity of depressive episode in relation to antidepressant-placebo response, Neuropsychopharmacology, 4, 125
- Klok, 1981, Fluvoxamine and clomipramine in depressed patients: A double blind clinical study, Acta Psychiatrica Scandinavica, 64, 1, 10.1111/j.1600-0447.1981.tb00756.x · DOI
- Manfredonia, 1992, Memory impairments in depression, Clinical Neuropharmacology, 15, 568, 10.1097/00002826-199202001-01108 · doi:10.1097/00002826-199202001-01108
- Muck-Seler, 1991, Effect of antidepressant treatment on platelet 5-HT content and relation to therapeutic outcome in unipolar depressive patients, Journal of Affective Disorders, 23, 157, 10.1016/0165-0327(91)90028-Q · DOI
- Murasaki, 1998, A late clinical phase ii study of sme3110 (fluvoxamine maleate), a selective serotonin reuptake inhibitor, in the treatment of depression and depressive state: an investigation of an optimal dose range using imipramine as a comparator, Rinsyoiyaku (Journal of clinical therapeutics & medicine), 14, 919
- Namiki, 1996, A clinical phase iii study of sme3110 (fluvoxamine maleate) in depressed patients at the department of internal medicine: a double-blind, comparative study with trazodone hydrochloride, Rinsyoiyaku, 12, 651
- Nicolini H Herrera K Pez F Camarena B Guajardo R De la Fuente JR Temperament, character, and molecular genotypes as predictors of antidepressant response XXth Collegium Internationale Neuro psychopharmacologicum Melbourne, Australia; 1996 · doi:10.1016/0924-977x(96)87893-x
- Nolen, 1998, Treatment strategy in depression I Non-tricyclic and selective reuptake inhibitors in resistant depression: a double-blind partial crossover study on the effects of oxaprotiline and fluvoxamine, Acta Psychiatrica Scandinavica, 78, 668, 10.1111/j.1600-0447.1988.tb06402.x · DOI
- Phanjoo, 1991, Double-blind comparative multicentre study of fluvoxamine and mianserin in the treatment of major depressive episode in elderly people, Acta Psychiatrica Scandinavica, 83, 476, 10.1111/j.1600-0447.1991.tb05579.x · DOI
- Poldinger, 1991, A functional-dimensional approach to depression: serotonin deficiency as a target syndrome in a comparison of 5-hydroxytryptophan and fluvoxamine, Psychopathology, 24, 53, 10.1159/000284698 · DOI
- Price, 1989, Effects of desipramine and fluvoxamine treatment on the prolactin response to tryptophan. Serotonergic function and the mechanism of antidepressant action, Archives of General Psychiatry, 46, 625, 10.1001/archpsyc.1989.01810070051009 · DOI
- Price, 1986, Variability of response to lithium augmentation in refractory depression, American Journal of Psychiatry, 143, 1387, 10.1176/ajp.143.11.1387 · DOI
- Ravindran, 1995, Stressful life events and coping styles in relation to dysthymia and major depressive disorder: Variations associated with alleviation of symptoms following pharmacotherapy, Progress in Neuro-Psychopharmacology & Biological Psychiatry, 19, 637, 10.1016/0278-5846(95)00108-8 · DOI
- Sacchetti, 1994, Are SSRI antidepressants a clinically homogeneous class of compounds?, Lancet, 344, 126, 10.1016/S0140-6736(94)91310-2 · DOI
- Sacchetti, 1997, Effectiveness of fluvoxamine and paroxetine in major depressives with psychotic features, Human Psychopharmacology, 12, 277, 10.1002/(SICI)1099-1077(199705/06)12:3<277::AID-HUP858>3.0.CO;2-E · doi:10.1002/(sici)1099-1077(199705/06)12:3<277::aid-hup858>3.0.co;2-e
- Schanda, 1979, Repolarisation disturbances in the ECG under antidepressant drugs. A comparison of two drugs, differing in chemical structure and pharmacological profile, Pharmakopsychiatrie, Neuro-Psychopharmakologie, 12, 338, 10.1055/s-0028-1094628 · doi:10.1055/s-0028-1094628
- Serretti, 2004, Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders, American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, 129, 36, 10.1002/ajmg.b.30027 · DOI
- Sheline, 1997, Correlated reductions in cerebrospinal fluid 5-HIAA and MHPG concentrations after treatment with selective serotonin reuptake inhibitors, Journal of Clinical Psychopharmacology, 17, 11, 10.1097/00004714-199702000-00003 · DOI
- Uzunova, 1998, Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine, Proceedings of the National Academy of Sciences of the United States of America, 95, 3239, 10.1073/pnas.95.6.3239 · DOI · Paper page
- Vandel, 1995, Fluvoxamine and fluoxetine: Interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients, Pharmacological Research, 31, 347, 10.1016/1043-6618(95)80088-3 · DOI
- Birkenhager, 2004, Comparison of two-phase treatment with imipramine or fluvoxamine, both followed by lithium addition, in inpatients with major depressive disorder, American Journal of Psychiatry, 161, 2060, 10.1176/appi.ajp.161.11.2060 · DOI
- Broek, 2004, A double-blind randomized study comparing imipramine with fluvoxamine in depressed inpatients, Psychopharmacology, 175, 481, 10.1007/s00213-004-1853-3 · DOI
- White, 1990, Fluvoxamine in the treatment of tricyclic-resistant depression, Psychiatric Journal of the University of Ottawa, 15, 156
- Yu, 2001, A comparative study of Luvox and amitriptyline in patients with major depression, Medical Journal of Chinese Civil Administration, 13, 227
- Zanardi, 2000, Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study, Journal of Clinical Psychiatry, 61, 26, 10.4088/JCP.v61n0107 · DOI
- Berlin, 1998, Early predictors of two month response with mianserin and selective serotonin reuptake inhibitors and influence of definition of outcome on prediction, European Psychiatry, 13, 138, 10.1016/S0924-9338(98)80137-5 · DOI
- Donovan, 1993, The efficacy and tolerability of dothiepin versus serotonin specific reuptake inhibitors in the treatment of depression, European Neuropsychopharmacology, 3, 331, 10.1016/0924-977X(93)90108-X · DOI
- Entsuah, 2002, Venlafaxine offers significant therapeutic benefits over existing SSRI treatments irrespective of the patient's depressive duration, European Neuropsychopharmacology, 12 Suppl 3, S238
- Faludi, 1989, Fluvoxamine versus maprotiline (Ludiomil) in the treatment of depression, IDeggyogyaszati Szemle, 46, 116
- Mallick, 2003, Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo, Journal of clinical psychiatry, 64, 321, 10.4088/JCP.v64n0315 · DOI
- Naito, 2007, Gender differences in the clinical effects of fluvoxamine and milnacipran in Japanese major depressive patients, Psychiatry and Clinical Neurosciences, 61, 421, 10.1111/j.1440-1819.2007.01679.x · DOI
- Ushiroyama T. Ikeda A. Ueki, 2004, Evaluation of double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients in menopause transition, Journal of Medicine, 35, 151
- Anderson, 1994, The efficacy of selective serotonin reuptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants, J Psychopharmacol, 8, 238, 10.1177/026988119400800407 · DOI · Paper page
- Anderson, 1998, SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability, Depression and Anxiety, 7 Suppl 1, 11, 10.1002/(SICI)1520-6394(1998)7:1+<11::AID-DA4>3.0.CO;2-I · DOI · Paper page
- Anderson, 2000 Mar, Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines.British Association for Psychopharmacology, Journal of Psychopharmacology, 14, 3, 10.1177/026988110001400101 · DOI · Paper page
- Anderson, 2001, Guidelines for choice of selective serotonin reuptake inhibitor in depressive illness, Advances in psychiatric treatment, 7, 170, 10.1192/apt.7.3.170 · DOI
- American Psychiatric Association, 1994, Diagnostic and Statistical Manual of Mental Disorders
- American Psychiatric Association, 2000, Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association, American Journal of Psychiatry, 157, 1
- Barbui, 2000, Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD002791 · DOI
- Barbui, 2004 Apr, "Wish bias" in antidepressant drug trials?, Journal of Clinical Psychopharmacology, 24, 126, 10.1097/01.jcp.0000115665.45074.0d · DOI
- Barbui, 2008, Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials, Canadian Medical Association Journal, 178, 296, 10.1503/cmaj.070693 · DOI
- Bhandari, 2004, Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials, Canadian Medical Association Journal, 170, 477
- Bucher, 1997, The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials, Journal of clinical epidemiology, 50, 683, 10.1016/S0895-4356(97)00049-8 · DOI · Paper page
- Buchkowsky, 2004, Industry sponsorship and authorship of clinical trials over 20 years, Annals of Pharmacotherapy, 38, 579, 10.1345/aph.1D267 · DOI
- Burton, 1991, A review of fluvoxamine and its uses in depression, International Clinical Psychopharmacology, 6 Suppl 3, 1-17; discussio
- Churchill, 2009, Reboxetine versus other antidepressive agents for depression, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD007852 · DOI
- Cipriani, 2005, Fluoxetine versus other types of pharmacotherapy for depression, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD004185.pub2 · DOI
- Cipriani, 2006, Are all antidepressants really the same? The case of fluoxetine: a systematic review, Journal of Clinical Psychiatry, 67, 850, 10.4088/JCP.v67n0601 · DOI
- Cipriani, 2007, Paroxetine versus other anti-depressive agents for depression, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006531 · DOI
- Cipriani, 2007, Venlafaxine versus other anti-depressive agents for depression, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006530 · DOI
- Cipriani, 2009, Sertraline versus other antidepressive agents for depression, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006117.pub2 · DOI · Paper page
- Ciuna, 2004, Are we going to increase the use of antidepressants up to that of benzodiazepines?, European Journal of Clinical Pharmacology, 60, 629, 10.1007/s00228-004-0810-8 · DOI
- Claassen, 1977, Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor, British Journal of Pharmacology, 60, 505, 10.1111/j.1476-5381.1977.tb07528.x · DOI · Paper page
- Depression Guideline, 1993, Depression in primary care: Vol 2
- Dozois, 2004, Depression, 259
- Edwards, 1999, Systematic review and guide to selection of selective serotonin reuptake inhibitors, Drugs, 57, 507, 10.2165/00003495-199957040-00005 · DOI · Paper page
- Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, British Medical Journal, 315, 629, 10.1136/bmj.315.7109.629 · DOI · Paper page
- Ellis, 2004, Australian and New Zealand clinical practice guidelines for the treatment of depression, Australian and New Zealand Journal of Psychiatry, 38, 389, 10.1080/j.1440-1614.2004.01377.x · DOI · Paper page
- Feighner, 1972, Diagnostic criteria for use in psychiatric research, Archives of General Psychiatry, 26, 57, 10.1001/archpsyc.1972.01750190059011 · DOI · Paper page
- Fuller, 1987, Serotonin reuptake blockers in vitro and in vivo, Journal of Clinical Psychopharmacology, 7, 36S
- Furukawa, 2002, Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review, British Medical Journal, 325, 991, 10.1136/bmj.325.7371.991 · DOI
- Furukawa, 2007, Association between unreported outcomes and effect size estimates in Cochrane meta-analyses, JAMA, 297, 468, 10.1001/jama.297.5.468-b · DOI
- Geddes, 2006, SSRIs versus other antidepressants for depressive disorder, Cochrane Database of Systematic Reviews
- Goldberg, 1991, Common mental disorders : a bio-social model
- Guaiana, 2005, Antidepressant drug consumption and public health indicators in Italy, 1955 to 2000, Journal of Clinical Psychiatry, 66, 750, 10.4088/JCP.v66n0612 · DOI
- Guaiana, 2007, Amitriptyline for depression, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD004186.pub2 · DOI · Paper page
- Guy, 1976, Clinical Global Impressions - ECDEU Asessment Manual Psychopharmacology (DHEW Publ No ADM 76-338)
- Hall, 1995, Global Assessment of Functioning - a modified scale, Psychosomatics, 36, 267, 10.1016/S0033-3182(95)71666-8 · DOI · Paper page
- Hamilton, 1960, A rating scale of depression, Journal of Neurology, 23, 56
- Hammad, 2006, Suicidality in pediatric patients treated with antidepressant drugs, Archives of General Psychiatry, 63, 332, 10.1001/archpsyc.63.3.332 · DOI · Paper page
- Higgins, 2003, Measuring inconsistency in meta-analyses, British Medical Journal, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
- Higgins, 2008. Available from www.cochrane-handbook.org, Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]., 10.1002/9780470712184 · DOI · Paper page
- Imperadore, 2007, Citalopram versus other anti-depressive agents for depression, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006534 · DOI
- Ioannidis, 2006, Indirect comparisons: the mesh and mess of clinical trials, Lancet, 368, 1470, 10.1016/S0140-6736(06)69615-3 · DOI
- Khan, 2003, Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports, Neuropsychopharmacology, 28, 552, 10.1038/sj.npp.1300059 · DOI · Paper page
- Lecrubier, 1996 Sep, Clinical efficacy of milnacipran: placebo-controlled trials, International Clinical Psychopharmacology, 11, 29, 10.1097/00004850-199609004-00004 · DOI
- Linde, 2008, St John's wort for major depression, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD000448.pub3 · DOI · Paper page
- Lopez-Ibor, 1996, Milnacipran and selective serotonin reuptake inhibitors in major depression, International Clinical Psychopharmacology, 11, 41, 10.1097/00004850-199609004-00006 · DOI
- Lu, 2006, Assessing evidenceinconsistency in mixed treatmentcomparisons, Journal of American StatisticalAssociation, 101, 447–59
- Mackay, 1997, A comparison if fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies, Pharmacoepidemiology and Drug Safety, 6, 235–246, 10.1002/(SICI)1099-1557(199707)6:4<235::AID-PDS293>3.0.CO;2-3 · DOI
- Montgomery, 2004, An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia, Controlled clinical trials, 25, 598, 10.1016/j.cct.2004.09.002 · DOI
- Mottram, 2006, Antidepressants for depressed elderly, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD003491.pub2 · DOI · Paper page
- Nakagawa, 2007, Milnacipran versus other anti-depressive agents for depression, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006529 · DOI
- NICE, 2004, Depression: management of depression in primary and secondary care
- Nose, 2007, Duloxetine versus other anti-depressive agents for depression, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006533 · DOI
- Okamura, 2006, Remission rates with milnacipran 100mg/day and 150 mg/day in the long-term treatment of major depression, Clinical Drug Investigation, 26, 135, 10.2165/00044011-200626030-00003 · DOI
- Perucca, 1994, Clinical pharmacokinetics of fluvoxamine, Clinical Pharmacokinetics, 27, 175, 10.2165/00003088-199427030-00002 · DOI
- Procyshyn, 2004, Prevalence and outcomes of pharmaceutical industry-sponsored clinical trials involving clozapine, risperidone, or olanzapine, Canadian Journal of Psychiatry, 49, 601, 10.1177/070674370404900905 · DOI
200 of 217 shown
Cited by
Citalopram versus other anti-depressive agents for depression
Cipriani, A., Purgato, M., Furukawa, T. A., Trespidi, C., Imperadore, G., Signoretti, A., Churchill, R., Watanabe, N., & Barbui, C. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006534.pub2 · Cited by 311
Self-citationSertraline versus other antidepressive agents for depression
Cipriani, A., La Ferla, T., Furukawa, T. A., Signoretti, A., Nakagawa, A., Churchill, R., McGuire, H., & Barbui, C. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006117.pub4 · Cited by 299
Self-citationNewer generation antidepressants for depressive disorders in children and adolescents
Hetrick, S. E., McKenzie, J. E., Cox, G. R., Simmons, M. B., & Merry, S. N. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004851.pub3 · Cited by 291
Fluoxetine versus other types of pharmacotherapy for depression
Magni, L. R., Purgato, M., Gastaldon, C., Papola, D., Furukawa, T. A., Cipriani, A., & Barbui, C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004185.pub3 · Cited by 252
Self-citationOliva, V., Lippi, M., Paci, R., Del Fabro, L., Delvecchio, G., Brambilla, P., De Ronchi, D., Fanelli, G., & Serretti, A. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110266 · Cited by 219
Metadata
- Authors
- Omori, I. M., Watanabe, N., Nakagawa, A., Cipriani, A., Barbui, C., McGuire, H., Churchill, R., & Furukawa, T. A.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2010-03-17
- Volume
- 2013
- Issue
- 9
- Pages
- CD006114-CD006114
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W4210997607
- Cited by
- 209
- References
- 28
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.